12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet [Wellbutrin] — RxCUI 993537
RxNorm drug concept · Semantic branded drug
RxCUI 993537
Semantic branded drug · SBD
● Current RxNorm concept 3 FDA products
3 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI993537
Official name12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet [Wellbutrin]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as12 HR Wellbutrin 200 MG Extended Release Oral Tablet; Wellbutrin SR 200 MG 12HR Extended Release Oral Tablet; Wellbutrin SR 200 MG 12 HR Extended Release Oral Tablet
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)672 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Bupropion: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Bupropion treats major depressive disorder. Some extended-release products, like Aplenzin and bupropion XL, can also prevent seasonal affective disorder, the depression that return...
- Take it by mouth exactly as prescribed. XL tablets are taken once in the morning, with or without food, and must be swallowed whole. Your doctor will usually raise the dose gradual...
- The most common ones are dry mouth, nausea, trouble sleeping, dizziness, headache, anxiety and tremor. Call your doctor right away if you have a seizure, new suicidal thoughts, sev...
- It's best to limit or avoid alcohol. Rare neuropsychiatric events and lower alcohol tolerance have been reported. Never suddenly stop heavy drinking while on bupropion without talk...
🕸️ Concept Web — How 12 HR bupropion hydrochloride 200 MG Extended Re... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet [Wellbutrin]
RxCUI 993537 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Bupropion
42347IN -
Bupropion hydrochloride
203204PIN
-
Bupropion
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Wellbutrin
42568BN
-
Wellbutrin
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Bupropion Extended Release Oral Tablet
378354SCDF -
Bupropion hydrochloride Extended Release Oral Tablet
2648043SCDFP -
Bupropion Oral Product
1151365SCDG -
Bupropion Pill
1151366SCDG -
Bupropion hydrochloride Oral Product
2659331SCDGP -
Bupropion hydrochloride Pill
2661650SCDGP -
Bupropion Extended Release Oral Tablet [Wellbutrin]
491056SBDF -
Bupropion hydrochloride Extended Release Oral Tablet [Wellbutrin]
2656792SBDFP - +5 more in this family
-
Bupropion Extended Release Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet
993536SCD -
Bupropion hydrochloride 200 MG
993532SCDC -
Bupropion hydrochloride 200 MG [Wellbutrin]
993534SBDC
-
12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet
SCD · 993536 -
Bupropion hydrochloride 200 MG
SCDC · 993532 -
Bupropion Extended Release Oral Tablet
SCDF · 378354 -
Bupropion hydrochloride Extended Release Oral Tablet
SCDFP · 2648043 -
Bupropion Oral Product
SCDG · 1151365 -
Bupropion Pill
SCDG · 1151366 -
Bupropion hydrochloride Oral Product
SCDGP · 2659331 -
Bupropion hydrochloride Pill
SCDGP · 2661650
Brand-Name Concepts
-
Bupropion hydrochloride 200 MG [Wellbutrin]
SBDC · 993534 -
Bupropion Extended Release Oral Tablet [Wellbutrin]
SBDF · 491056 -
Bupropion hydrochloride Extended Release Oral Tablet [Wellbutrin]
SBDFP · 2656792 -
Wellbutrin Oral Product
SBDG · 1187946 -
Wellbutrin Pill
SBDG · 1187947 -
Wellbutrin
BN · 42568
📦 FDA Products & Package NDCs
3 products · 3 package NDCs
3 package NDCs map to RxCUI 993537 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00173-0135-55 | 60 TABLET, FILM COATED in 1 BOTTLE (0173-0135-55) | WELLBUTRIN SR | GlaxoSmithKline LLC | 1996-11-15 |
| 00173-0722-00 | 60 TABLET, FILM COATED in 1 BOTTLE (0173-0722-00) | WELLBUTRIN SR | GlaxoSmithKline LLC | 2002-06-25 |
| 00173-0947-55 | 60 TABLET, FILM COATED in 1 BOTTLE (0173-0947-55) | WELLBUTRIN SR | GlaxoSmithKline LLC | 1996-11-15 |
Observed labelers:
GlaxoSmithKline LLC (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.